174 related articles for article (PubMed ID: 35726194)
41. Short-term hyperthyroidism followed by transient pituitary hypothyroidism in a very low birth weight infant born to a mother with uncontrolled Graves' disease.
Higuchi R; Kumagai T; Kobayashi M; Minami T; Koyama H; Ishii Y
Pediatrics; 2001 Apr; 107(4):E57. PubMed ID: 11335778
[TBL] [Abstract][Full Text] [Related]
42. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
43. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer.
Lima N; Cavaliere H; Tomimori E; Knobel M; Medeiros-Neto G
J Endocrinol Invest; 2002 Feb; 25(2):110-5. PubMed ID: 11929080
[TBL] [Abstract][Full Text] [Related]
44. High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism.
Romão R; Rubio IG; Tomimori EK; Camargo RY; Knobel M; Medeiros-Neto G
Thyroid; 2009 Sep; 19(9):945-51. PubMed ID: 19678745
[TBL] [Abstract][Full Text] [Related]
45. The spectrum of inappropriate pituitary thyrotropin secretion associated with hyperthyroidism.
Gharib H; Carpenter PC; Scheithauer BW; Service FJ
Mayo Clin Proc; 1982 Sep; 57(9):556-63. PubMed ID: 7109684
[TBL] [Abstract][Full Text] [Related]
46. Is empirical radioactive iodine therapy still a valid approach to patients with thyroid cancer and elevated thyroglobulin?
Rosario PW; Mourão GF; dos Santos JB; Calsolari MR
Thyroid; 2014 Mar; 24(3):533-6. PubMed ID: 24067080
[TBL] [Abstract][Full Text] [Related]
47. Serum thyroglobulin is associated with orbitopathy in Graves' disease.
Khamisi S; Lundqvist M; Emadi P; Almby K; Ljunggren Ö; Karlsson FA
J Endocrinol Invest; 2021 Sep; 44(9):1905-1911. PubMed ID: 33515213
[TBL] [Abstract][Full Text] [Related]
48. Effect of thyrotropin-releasing hormone on serum thyroid hormones: a study in the patients with untreated and treated Graves' disease and subacute thyroiditis.
Sato A; Yamada T; Aizawa T; Ichikawa K; Komiya I; Takasu N; Takemura Y
J Clin Endocrinol Metab; 1995 Jul; 80(7):2173-7. PubMed ID: 7608274
[TBL] [Abstract][Full Text] [Related]
49. OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS.
Jasim S; Iniguez-Ariza NM; Hilger CR; Chintakuntlawar AV; Ryder MM; Morris JC; Bible KC
Endocr Pract; 2017 Oct; 23(10):1254-1261. PubMed ID: 28816536
[TBL] [Abstract][Full Text] [Related]
50. [T3 hyperthyroidism with metastatic follicular thyroid carcinoma in substitution therapy].
Lang M; Flesch M
Nuklearmedizin; 1996 Oct; 35(5):186-9. PubMed ID: 9005415
[TBL] [Abstract][Full Text] [Related]
51. Serum Thyroid Hormone Balance in Levothyroxine Monotherapy-Treated Patients with Atrophic Thyroid After Radioiodine Treatment for Graves' Disease.
Ito M; Kawasaki M; Danno H; Kohsaka K; Nakamura T; Hisakado M; Yoshioka W; Kasahara T; Kudo T; Nishihara E; Fukata S; Nishikawa M; Nakamura H; Miyauchi A
Thyroid; 2019 Oct; 29(10):1364-1370. PubMed ID: 31411123
[No Abstract] [Full Text] [Related]
52. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
[TBL] [Abstract][Full Text] [Related]
53. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer.
Burmeister LA; Goumaz MO; Mariash CN; Oppenheimer JH
J Clin Endocrinol Metab; 1992 Aug; 75(2):344-50. PubMed ID: 1639933
[TBL] [Abstract][Full Text] [Related]
54. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma.
Golger A; Fridman TR; Eski S; Witterick IJ; Freeman JL; Walfish PG
J Endocrinol Invest; 2003 Oct; 26(10):1023-31. PubMed ID: 14759077
[TBL] [Abstract][Full Text] [Related]
55. Thyrotropin-producing pituitary adenoma simultaneously existing with Graves' disease: a case report.
Arai N; Inaba M; Ichijyo T; Kagami H; Mine Y
J Med Case Rep; 2017 Jan; 11(1):9. PubMed ID: 28061802
[TBL] [Abstract][Full Text] [Related]
56. Improvement of immunologic abnormalities associated with hyperthyroidism of Graves' disease during methimazole treatment.
Murakami M; Koizumi Y; Aizawa T; Yamada T; Ishihara M; Hasegawa Y; Ogata H; Kamoi K; Kaneko K
Horm Metab Res; 1988 Apr; 20(4):235-8. PubMed ID: 3397034
[TBL] [Abstract][Full Text] [Related]
57. Management of coexisting thyrotropin/growth-hormone-secreting pituitary adenoma and papillary thyroid carcinoma: a therapeutic challenge.
Nguyen HD; Galitz MS; Mai VQ; Clyde PW; Glister BC; Shakir MK
Thyroid; 2010 Jan; 20(1):99-103. PubMed ID: 20067380
[TBL] [Abstract][Full Text] [Related]
58. Pneumatosis intestinalis associated with lenvatinib during thyroid cancer treatment: a case report.
Toda S; Iwasaki H; Murayama D; Isoda M; Nakayama H; Suganuma N; Masudo K
J Med Case Rep; 2021 Nov; 15(1):556. PubMed ID: 34763724
[TBL] [Abstract][Full Text] [Related]
59. Influence of high tissue-absorbed dose on anti-thyroid antibodies in radioiodine therapy of Graves' disease patients.
Listewnik MH; Piwowarska-Bilska H; Jasiakiewicz K; Birkenfeld B
Adv Clin Exp Med; 2021 Sep; 30(9):913-921. PubMed ID: 34418335
[TBL] [Abstract][Full Text] [Related]
60. Hyperthyroidism due to inappropriate TSH secretion with associated hyperprolactinaemia--a case report and review of the literature.
Spitz IM; Sheinfeld M; Glasser B; Hirsch HJ
Postgrad Med J; 1984 May; 60(703):328-35. PubMed ID: 6429655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
